Single Dose Study to Investigate the Pharmacokinetics of Odanacatib (MK-0822) in Subjects With Hepatic Insufficiency

Trial Profile

Single Dose Study to Investigate the Pharmacokinetics of Odanacatib (MK-0822) in Subjects With Hepatic Insufficiency

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Oct 2013

At a glance

  • Drugs Odanacatib (Primary)
  • Indications Male osteoporosis; Postmenopausal osteoporosis
  • Focus Pharmacokinetics
  • Sponsors Merck & Co
  • Most Recent Events

    • 08 Oct 2013 Results presented at the 35th Annual Meeting of the American Society for Bone and Mineral Research.
    • 15 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 24 Apr 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top